Showing 1 - 6 results of 6 for search 'Samuel R Denmeade', query time: 0.03s Refine Results
  1. 1
    Albumin-linked prostate-specific antigen-activated thapsigargin- and niclosamide-based molecular grenades targeting the microenvironment in metastatic castration-resistant prostate cancer

    Albumin-linked prostate-specific antigen-activated thapsigargin- and niclosamide-based molecular grenades targeting the microenvironment in metastatic castration-resistant prostate... by Emmanuel S. Akinboye, W. Nathaniel Brennen, Samuel R. Denmeade, John T. Isaacs

    Published 2019-01-01
    Get full text
    Article
  2. 2
    Mipsagargin: The Beginning—Not the End—of Thapsigargin Prodrug-Based Cancer Therapeutics

    Mipsagargin: The Beginning—Not the End—of Thapsigargin Prodrug-Based Cancer Therapeutics by John T. Isaacs, William Nathaniel Brennen, Søren Brøgger Christensen, Samuel R. Denmeade

    Published 2021-12-01
    Get full text
    Article
  3. 3
    Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss

    Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss by Mark C. Markowski, Hao Wang, Angelo M. De Marzo, Michael T. Schweizer, Emmanuel S. Antonarakis, Samuel R. Denmeade

    Published 2022-07-01
    Get full text
    Article
  4. 4
    The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin.

    The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin. by Sushant K Kachhap, Dennis Faith, David Z Qian, Shabana Shabbeer, Nathan L Galloway, Roberto Pili, Samuel R Denmeade, Angelo M DeMarzo, Michael A Carducci

    Published 2007-09-01
    Get full text
    Article
  5. 5
    Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial

    Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial by Mark C. Markowski, Mary-Ellen Taplin, Rahul Aggarwal, Laura A. Sena, Hao Wang, Hanfei Qi, Aliya Lalji, Victoria Sinibaldi, Michael A. Carducci, Channing J. Paller, Catherine H. Marshall, Mario A. Eisenberger, David E. Sanin, Srinivasan Yegnasubramanian, Carolina Gomes-Alexandre, Busra Ozbek, Tracy Jones, Angelo M. De Marzo, Samuel R. Denmeade, Emmanuel S. Antonarakis

    Published 2024-01-01
    Get full text
    Article
  6. 6
    Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC

    Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC by Laura A. Sena, Rajendra Kumar, David E. Sanin, Elizabeth A. Thompson, D. Marc Rosen, Susan L. Dalrymple, Lizamma Antony, Yuhan Yang, Carolina Gomes-Alexandre, Jessica L. Hicks, Tracy Jones, Kiara A. Bowers, Jillian N. Eskra, Jennifer Meyers, Anuj Gupta, Alyza Skaist, Srinivasan Yegnasubramanian, Jun Luo, W. Nathaniel Brennen, Sushant K. Kachhap, Emmanuel S. Antonarakis, Angelo M. De Marzo, John T. Isaacs, Mark C. Markowski, Samuel R. Denmeade

    Published 2022-12-01
    Get full text
    Article

Search Tools: